Tetra Discovery Partners   Report issue

For profit Phase 1 Phase 3
Founded: Grand Rapids MI United States (2010)
Status: Acquired by Shionogi (2020)

Organization Overview

First Clinical Trial
2015
NCT02648672
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Tetra Discovery Partners

Active Ingredients

Drugs in Phase 3 Trials (1)

bpn14770 (9 trials)

Drugs in Phase 1 Trials (2)

donepezil (aricept) (1 trial)

scopolamine (transderm scop) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cognitive Dysfunction (Phase 1)

Fragile X Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 3